Moreover, targeted therapies that inhibit FGF receptor 4 (FGFR4) can enhance the effectiveness of anti-PD-1 therapy by reducing PD-L1 expression and impeding Treg differentiation, further augmenting the anti-tumor immune response (Yi et al., 2021). Here, CD274 is linked to neoplasm.